CPIX — CUMBERLAND PHARMACEUTICALS INC

Nasdaq · Health Care · Pharmaceuticals · CIK 1087294 ·
Last close
$7.84
Market Cap
$117.47M
52W High
$8.45
52W Low
$4.19
ADV30
120,282
Next earnings
2026-11-03
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026
Mar 2026 9,131,317 7,197,428 -3,129,292 -3,289,639 70,995,020 11,007,245 49,692,008
Dec 2025 13,678,651 11,437,307 -1,371,202 -1,411,692 76,823,992 11,444,693 52,279,770
Sep 2025 8,292,362 7,303,602 -1,965,260 -1,940,764 65,898,560 15,196,745 40,097,856

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,421,029
Investing CF
$-3,539,484
Financing CF
$-1,982,714
CapEx
$-1,323,419
Dividends Paid
Buybacks
$-78,611
EPS Diluted TTM
$-0.71
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-30,093,698
Inventory
$5,453,836
Receivables
$14,261,978
ST Investments
EBIT TTM
$-6,784,162
Pretax Income TTM
$-7,202,189
Interest Exp TTM
$418,027
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$44,304,312
EBITDA
$1,096,723
Free Cash Flow
$-191,169
Enterprise Value
$115,140,984
Total Cash
$3,862,402
Total Debt
$4,714,184
Shares Out
14,983,107
Trailing EPS
$-0.22
Book Value
$1.16
ROE
-14.4%
ROA
-2.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 44,521,431 -2,791,993 -2,836,128 76,823,992 52,279,770 4,932,522
Dec 2024 37,867,945 -6,432,409 -6,479,770 75,583,410 53,037,433 -612,186
Dec 2023 39,552,507 -9,554,661 -6,279,320 81,776,075 52,516,206 6,093,821
Dec 2022 42,010,949 -5,704,929 -5,570,241 92,925,158 56,951,152 8,453,396

TTM Snapshot

Revenues TTM
$31,875,677
NetIncome TTM
$1,180,122
OpCashFlow TTM
$0
Assets (Latest)
$75,583,410
Forward EPS
$0.14

Max Pain — expiry 2026-10-16

max pain strike: $5.00 · spot: $7.84 · call oi: 1,065 · put oi: 312
Expected Move to 2026-10-16: ±$2.92 (37.31%) — implied range $4.92$10.77 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
COYA Coya Therapeutics, Inc. $116.35M $4.96
BMEA Biomea Fusion, Inc. $115.25M $1.59
NTHI NEONC TECHNOLOGIES HOLDINGS, INC. $121.64M $4.69
RFL Rafael Holdings, Inc. $112.16M $2.19
GNLX GENELUX Corp $123.07M $2.72

News headlines (Yahoo Finance, 1h cache)

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
2026-07-28 20:05 · Yahoo
/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./
2026-07-13 15:20 · Yahoo
Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals
2026-07-01 13:00 · Yahoo
Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex
2026-07-01 13:00 · Yahoo
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
2026-06-26 15:00 · Yahoo
Cumberland Posts Loss in Q1 Amid $100M Apotex Deal Plan
2026-05-06 14:12 · Yahoo
Cumberland Pharmaceuticals Inc. Q1 2026 Earnings Call Summary
2026-05-06 12:30 · Yahoo
Cumberland Pharmaceuticals Q1 Earnings Call Highlights
2026-05-05 23:43 · Yahoo
The Zacks Analyst Blog Highlights Alphabet, Apple, Micron Technology, Cumberland Pharmaceuticals and AmeriServ Financial
2026-05-28 10:15 · Yahoo
Cumberland Pharmaceuticals Inc (CPIX) (Q2 2026) Earnings Call Highlights: Strategic ...
2026-08-05 05:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.